Oct 2, 2020 | News
Inimmune is a collaborator in the University of Montana’s effort to bring opioid vaccines to clinical trials.
Jul 9, 2020 | News
(Missoula, MT) Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. It was the Missoula-based company’s first outside...
Jul 9, 2020 | News
Inimmune lands the an $22 million dollar investment, let by Two Bear Capital. The investment is believed to be largest Series A funding in state history; Inimmune, which is based in Missoula, Montana, specializes in adjuvants for vaccines and has been developing a...
Jul 1, 2020 | News
Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded a $2 M grant from the National Institute for Allergy and Infectious Diseases (NIAID) under its Small Business Innovation Research (SBIR) Direct to Phase II program to advance a...
Jun 8, 2020 | News
Inimmune Corporation is joining in on efforts to develop a COVID-19 vaccine with a nasal spray that could offer protection against coronavirus. The research efforts are in collaboration with the University of Montana’s Center for Translational Medicine and Rocky...
Jun 7, 2020 | News
The science behind the silent killer. Here is how Inimmune is developing vaccines to help solve the opioid epidemic. Read full article: Science and the Silent Killer
